Inhibrx Biosciences, Inc.
Company Stats
- Market Cap
- $1.5B
- as of Sep 30, 2026
- Shares Outstanding
- 14.7M
- Free Float
- 62.9%
Income Statement
- Revenue
- $1.3M
- Operating Income
- -$135.0M
- Net Income
- -$140.1M
- EBITDA
- -$132.5M
- FCF Margin, 3Y Avg
- -39828.0%
- FCF Margin, Worst Year
- -98503.0%
Cash Flow
- Free Cash Flow
- -$129.8M
- FCF Yield
- -8.8%
- Owner FCF Yield
- -9.6%
Balance Sheet
- Cash & Equivalents
- $124.2M
Returns & Capital
- SBC, 3Y Avg
- $31.5M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $1.3M | -$129.8M | -9986.5% |
| FY2024 | $200,000 | -$197.0M | -98503.0% |
| FY2023 | $1.8M | -$197.9M | -10994.6% |
Annual filing data through FY ended December 31, 2025; shares and float as of October 15, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Microcap Insider Buying: Week Ending October 16, 2026
Stronger demand supports expansion as pricing diverges